###begin article-title 0
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR</italic>
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 9 14 <span type="species:ncbi:9606">human</span>
The HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR (epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellular ligands to intracellular signal transduction pathways resulting in receptor interaction and cross-activation. The most famous family member is HER2, which is a target in Herceptintrade mark therapy in metastatic status and also in adjuvant therapy of breast cancer in the event of dysregulation as a result of gene amplification and resulting protein overexpression. The HER2-related HER receptors have been shown to interact directly with HER2 receptors and thereby mutually affect their activity and subsequent malignant growth potential. However, the clinical outcome with regard to total HER receptor state remains largely unknown.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 85 93 85 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
We investigated HER1-HER4, at both the DNA and the protein level, using fluorescence in situ hybridisation (FISH) probes targeted to all four receptor loci and also immunohistochemistry in tissue microarrays derived from 278 breast cancer patients.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 166 168 166 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 186 191 186 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
We retrospectively found HER3 gene amplification with a univariate negative impact on disease-free survival (hazard ratio 2.35, 95% confidence interval 1.08 to 5.11, p = 0.031), whereas HER4 amplification showed a positive trend in overall and disease-free survival. Protein expression revealed no additional information.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 167 175 <span type="species:ncbi:9606">patients</span>
Overall, the simultaneous quantification of HER3 and HER4 receptor genes by means of FISH might enable the rendering of a more precise stratification of breast cancer patients by providing additional prognostic information. The continuation of explorative and prospective studies on all HER receptors will be required for an evaluation of their potential use for specific therapeutic targeting with respect to individualised therapy.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 33 36 33 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-erbB2</italic>
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 269 270 269 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 507 508 507 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 509 510 509 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 783 784 783 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Gene amplification of HER2 (HER2/neu, c-erbB2) receptor tyrosine kinase (RTK) is found in 10 to 25% of invasive breast carcinomas [1,2] and is associated with an unfavourable impact on the course of disease and reduced responsiveness to tamoxifen therapy, for example [3,4]. The HER2 receptor has frequently been described as dominantly triggering mitogenic signalling within the type 1 growth factor receptor family. As a ligandless orphan receptor, HER2 preferentially heterodimerises with its relatives [5,6] and thereby has an important role in signal triggering and amplification. Its malignant potential and its key role in enhanced cell proliferation, carcinogenesis, tumour progression and metastasis have frequently been proved in numerous preclinical and clinical studies [7].
###end p 11
###begin p 12
###xml 268 269 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 525 526 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 564 565 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 566 568 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 701 703 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 771 776 762 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 554 562 <span type="species:ncbi:9606">patients</span>
###xml 837 844 <span type="species:ncbi:9606">patient</span>
The overexpressed receptor protein is exploited as the therapeutic target for Herceptintrade mark, known as the humanised monoclonal antibody trastuzumab, in metastatic breast cancer and has recently proved useful in designing adjuvant treatment for breast carcinoma [8]. Moreover, strong HER2 expression represents the decisive molecular basis for tumour therapy targeted at the same receptor. However, a therapeutic benefit in terms of tumour regression, prolongation of recurrence-free survival and even overall survival [9] is found for about 50% of patients [9-11] depending on previous therapies, antibody resistance and combination with other chemotherapeutics such as paclitaxel or docetaxel [12]. This observation reflects the substantial insufficiency of using HER2 gene amplification or HER2 protein overexpression to predict patient responsiveness to Herceptin.
###end p 12
###begin p 13
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 381 386 <span type="species:ncbi:9606">human</span>
Hence, the identification of clinicopathological and molecular characteristics of breast cancer to enable more accurate prognosis of the course of disease and prediction of therapy response to antibodies or small enzyme-inhibiting molecules [13-15], for example, is a continuing challenge in the field of diagnostic pathology. To this end, the three additional members of the HER (human EGFR related)-RTK family HER1 (epidermal growth factor receptor (EGFR), c-erbB1), HER3 (c-erbB3) and HER4 (c-erbB4) are of particular interest because of their ability to interact directly with HER2 [16]. On the basis of their common evolutionary origin these receptors share a high degree of structural and functional homology, which is the molecular basis for receptor interaction and cross-activation [17]. Thus, HER-receptor activity and functionality depend on one another and thus the impact on tumour cell proliferation and growth is likely to be dependent on HER-receptor coexpression and communication.
###end p 13
###begin p 14
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 288 296 <span type="species:ncbi:9606">patients</span>
Several immunohistochemical studies have been undertaken to elucidate the coexpression profile of HER receptors in breast cancer, providing preliminary data on other HER receptors besides HER2, which may have an impact on the course of disease and therapy responsiveness in breast cancer patients [18-20].
###end p 14
###begin p 15
###xml 54 62 54 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 105 109 105 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 566 568 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 636 640 618 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 641 646 623 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 803 805 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 863 867 845 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 869 874 851 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 877 882 859 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 1050 1058 <span type="species:ncbi:9606">patients</span>
In this study we performed a four-target fluorescence in situ hybridisation (FISH) analysis of the HER1, HER2, HER3 and HER4 gene loci together with centromere quantification using 278 primary breast cancer samples compiled into a tissue microarray (TMA). Additionally, we immunohistochemically stained the receptor proteins and categorised staining intensity in accordance with EGFR pharmDXtrade mark and HercepTesttrade mark scoring guidelines. Furthermore, the results were compared with the Ki-67 proliferation index, a prognostic marker in early breast cancer [21]. Our objective was to determine the potential association between HER1-HER4 gene amplification or altered protein expression and outcome and course of disease, as well as with known clinicopathological breast cancer prognosticators [22]. We addressed the question of whether alteration in the HER1, HER3 or HER4 genes or their protein products conveys any prognostic value that is complementary to or independent of HER2 that would allow a more precise rendering of breast cancer patients into subgroups with different clinical outcomes based on HER-receptor analysis.
###end p 15
###begin p 16
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 155 160 155 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Our data indicate additional HER3 and HER4 prognostic markers in breast cancer that should be prospectively explored in further detail. The integration of HER3 and HER4 analysis into routine cancer diagnosis would provide valuable additional information. Further descriptive and particularly functional studies are required to understand their impact on the course of disease at the molecular and cellular levels [16,23] and will provide the basis for designing specific targeted therapeutics in terms of individualised disease management.
###end p 16
###begin title 17
Materials and methods
###end title 17
###begin p 18
This study was approved by the Institutional Review Board of the University of Regensburg, Germany.
###end p 18
###begin title 19
###xml 26 33 <span type="species:ncbi:9606">patient</span>
Breast tumour samples and patient characteristics
###end title 19
###begin p 20
###xml 569 570 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
###xml 461 469 <span type="species:ncbi:9606">patients</span>
###xml 687 695 <span type="species:ncbi:9606">patients</span>
Formalin-fixed paraffin-embedded tissue blocks from 278 female patients with invasive lobular or ductal unilateral primary breast cancer (median age 55 years; range 25 to 82 years) were obtained from the archives of the Institute of Pathology, Regensburg, Germany, and were derived from a consecutive series of sporadic breast cancers. The patients were not involved in any clinical trial. Clinical data were acquired by the Tumour Centre Inc., Regensburg. All patients underwent surgery between 1992 and 2002. The histopathological characteristics are listed in Table 1. The median follow-up period was 125.6 months (95% confidence interval (CI) 120.3 to 131.0). A total of 106 (38.1%) patients died, and 136 (48.9%) had a recurrence of breast cancer.
###end p 20
###begin p 21
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient age and histopathological characteristics of 278 breast carcinomas
###end p 21
###begin p 22
###xml 18 26 <span type="species:ncbi:9606">patients</span>
The median age of patients was 55 years (range 25 to 82 years).
###end p 22
###begin title 23
Tissue microarray (TMA) construction
###end title 23
###begin p 24
###xml 44 46 44 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 47 49 47 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
TMAs were prepared as described previously [24,25]. For each tumour a representative tumour section was selected from a haematoxylin/eosin-stained section of the donor block. Core cylinders with a diameter of 1.5 mm each were punched from this area with a thin-walled stainless steel tube and deposited into a recipient paraffin block. TMA sections were mounted on charged slides (SuperFrosttrade markPlus; Menzel GmbH, Braunschweig, Germany). Haematoxylin/eosin-stained TMA sections were used for reference histology.
###end p 24
###begin title 25
###xml 13 21 13 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
Fluorescence in situ hybridisation
###end title 25
###begin p 26
###xml 98 102 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 104 108 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 110 115 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 119 124 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
FISH was performed on 5 mum sections of the TMAs with the use of directly labelled DNA probes for HER1, HER2, HER3 and HER4 (ZytoVision Ltd., Bremerhaven, Germany). The probes identified locus-specific sequences for both the genes and the corresponding centromeres 7, 17, 12 and 2 to differentiate between gene amplification and polysomy of the respective chromosome.
###end p 26
###begin p 27
TMA sections were dewaxed for 40 minutes in an incubator at 72degreesC and twice for 10 minutes in xylene. After being rehydrated in a graded ethanol series and rinsed in distilled water, slides were placed in 0.01 M sodium citrate and steamed for 40 minutes in a water bath. Cell structures were digested in 0.1% pepsin (Sigma, Munich, Germany) and 0.01 M HCl for 10 minutes at 37degreesC. After washing in 2 x SSC (1 x SSC (standard saline citrate) is 150 mM sodium chloride and 15 mM sodium citrate, pH 7) and water, slides were dehydrated in graded alcohols and air-dried. Respective DNA probe sets (10 mul each) were applied to the TMA area of each section. Sections were coverslipped and the edges were sealed with rubber cement. For co-denaturation of the probe and target DNA, slides were placed for 5 minutes on a hotplate preheated to 73degreesC and than transferred overnight to a warmed hybridisation chamber at 37degreesC. After hybridisation, the rubber cement was removed and the slides were immersed successively in 4 x SSC plus 0.3% Igepal (Serva, Heidelberg, Germany), 2 x SSC and 1 x SSC for 10 minutes at 50degreesC. The slides were rinsed briefly in Millipore water and air-dried. Nuclei were counterstained with anti-fading DAPI (4',6-diamidino-2-phenylindole) Vectashield (Vector Laboratories, Burlingame, CA, USA) and were analysed by epifluorescence microscopy.
###end p 27
###begin title 28
###xml 25 33 25 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
Microscopy, fluorescence in situ hybridisation scoring and digital imaging
###end title 28
###begin p 29
###xml 748 749 727 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">z</italic>
Slides were imaged with an Axio Imager Z.1 (Zeiss, Gottingen, Germany) equipped with specific filter sets for DAPI fluorescence (excitation 365 +/- 20 nm, emission 450 +/- 25 nm; Zeiss), green fluorescence (excitation 500 +/- 10 nm, emission 535 +/- 15 nm) and red fluorescence (excitation 545 +/- 15 nm, emission 610 +/- 35 nm; AHF, Tubingen, Germany). Fluorescence images were obtained with a Plan-Apochromat lens (63x, numerical aperture 1.4) and recorded with a CCD (charge-coupled device) camera AxioCam MRm (Zeiss). The plug-in module ApoTometrade mark enabled the taking of pseudoconfocal, scattered out-of-focus light-free images using transmission grids and corresponding algorithms. To exclude the loss of FISH signals, three-dimensional z-stacks were generated. Each colour was recorded and digitally processed (filtering and contrast enhancement) using AxioVision 4.5 software (Zeiss). Corresponding images were superimposed.
###end p 29
###begin p 30
FISH scoring was performed by counting fluorescence signals in 25 malignant, non-overlapping cell nuclei for each case by two independent interpreters (AS, MB). The FISH ratio was assessed as the number of genes proportional to the number of centromeres.
###end p 30
###begin title 31
Immunohistochemistry
###end title 31
###begin p 32
###xml 186 187 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 513 514 512 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 456 461 <span type="species:ncbi:10090">mouse</span>
Immunostaining with anti-HER-receptor antibodies and MIB-1 (anti-Ki-67) was performed on 5 mum sections of the TMAs and applied in accordance with the manufacturer's instructions. Table 2 shows the antibody-specific staining and scoring characteristics. MIB-1 was regarded as positive when 30% or more of the nuclei in the punched tissue were stained. Interpretation was performed independently by two experienced pathologists (SS, AH). Stably transfected mouse fibroblasts proved specific immunostaining (Figure 1).
###end p 32
###begin p 33
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4</italic>
###xml 27 32 <span type="species:ncbi:10090">mouse</span>
###xml 96 111 <span type="species:ncbi:10029">Chinese hamster</span>
Anti-HER-immunostaining of mouse fibroblasts, stably transfected with HER1, HER2, HER3 or HER4. Chinese hamster ovary wild-type, Jurkat and the three additional transfected fibroblast cell lines served as negative controls (magnification of slide overview x16, magnification of cutout x400, small circle indicates magnified area).
###end p 33
###begin p 34
Characteristics for anti-HER and anti-Ki-67 immunostaining and scoring
###end p 34
###begin p 35
mAb, monoclonal antibody; pAb, polyclonal antibody; DAB, diaminobenzidine; EGFR, epidermal growth factor receptor.
###end p 35
###begin title 36
Statistical analyses
###end title 36
###begin p 37
###xml 505 515 505 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1&#8211;HER4 </italic>
###xml 625 635 625 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1&#8211;HER4 </italic>
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 855 857 855 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1449 1453 1449 1453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 1455 1460 1455 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 1464 1469 1464 1469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 1485 1489 1485 1489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 1594 1596 1594 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1849 1851 1847 1849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1852 1854 1850 1852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 150 157 <span type="species:ncbi:9606">patient</span>
###xml 186 194 <span type="species:ncbi:9606">Patients</span>
###xml 976 984 <span type="species:ncbi:9606">patients</span>
The primary outcome measure, overall survival, was calculated as the time from the date of diagnosis to death from any cause or the date on which the patient was last known to be alive. Patients lost to follow-up were treated as censored cases on the basis of the date they were last known to be alive. The secondary outcome measure was the disease-free survival, the time from diagnosis to the date of tumour-related death. Two outcome-orientated approaches were used to determine the cut-off points for HER1-HER4 FISH with regard to overall survival. First, we examined plots of the martingale residuals against the single HER1-HER4 FISH variables using the PROC LOESS option in SAS and chose DIRECT SMOOTH with a smoothing parameter of 2/3. Second, we applied the Contal and O'Quigley method [26], which is based on the log rank statistic and provides p values corrected for examining multiple potential cut-off points. The cut-off points obtained were then used to divide patients into two groups: amplified and non-amplified. Survival curves were generated by using the Kaplan-Meier method, and log-rank tests compared the distributions between groups. In addition, hazard ratios (HR values) with 95% CIs were estimated for a single covariate (treated as continuous, and where appropriate as a dichotomous variable) using the Cox proportional-hazards model. Finally, multivariate Cox models were fitted to assess the prognostic significance of HER1, HER3 and HER4 irrespective of HER2. For cut-off point determination an adjusted 10% level of significance was used. In all other analyses, p </= 0.05 (two-tailed) was considered significant. Statistical analyses were performed with SPSS version 13.0 and SAS version 9.1 software (SAS Institute, Cary, NC, USA). For cut-off point determination an SAS macro provided by Mandrekar and colleagues [27,28] was applied.
###end p 37
###begin title 38
Results
###end title 38
###begin p 39
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 309 311 309 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 289 296 <span type="species:ncbi:9606">patient</span>
Microarrays of paraffin-embedded breast cancer tissue from 278 patients were used to analyse gene amplification and protein expression of each member of the HER family. Furthermore, we analysed tumour and nodal status and tumour grading (Table 3) to indicate the representativeness of our patient collective (p < 0.001).
###end p 39
###begin p 40
Cox proportional hazards analysis for overall and disease-free survival
###end p 40
###begin p 41
###xml 45 47 45 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 290 298 290 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
Hazard ratios (HR), confidence intervals and p values of investigated parameters dependent on overall and disease-free survival (CI, confidence interval with lower and upper limits). All immunohistochemical and histological parameters were used as categorical variables. FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry.
###end p 41
###begin title 42
###xml 13 21 13 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
Fluorescence in situ hybridisation
###end title 42
###begin p 43
###xml 182 183 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
Newly designed probes for dual-colour FISH (courtesy of ZytoVision Ltd., Bremerhaven, Germany) were established to detect the gene and the centromere status of each receptor (Figure 2).
###end p 43
###begin p 44
###xml 5 15 5 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1&#8211;HER4 </italic>
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3</italic>
###xml 222 226 222 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4</italic>
###xml 51 58 <span type="species:ncbi:9606">patient</span>
Anti-HER1-HER4 FISH in breast cancer tissue of one patient (dual probes). HER1: red cen 7, green loc 7p11 (diploid); HER2: red cen 17, green loc 17q12 (amplified); HER3: green cen 12, red loc 12q13 (moderately amplified); HER4: green cen 2, red loc 2q33 (diploid); 4',6-diamidino-2-phenylindole core staining blue. Cen, centromere; loc, gene locus.
###end p 44
###begin p 45
###xml 27 37 27 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1&#8211;HER4 </italic>
###xml 66 67 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 199 204 199 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 264 269 264 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1 </italic>
###xml 370 374 370 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 380 384 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 386 391 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 395 399 395 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4</italic>
###xml 416 420 416 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 578 582 578 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 591 595 591 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3</italic>
###xml 604 608 604 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4</italic>
The ratio distributions of HER1-HER4 FISH are presented in Figure 3. Whereas HER2 ratios varied from 0.5 to 11.3, the study population was more homogeneous with regard to HER3 (range 0.5 to 2.3) and HER4 (range 0.6 to 1.5) and extremely homogeneous with regard to HER1 (range 0.7 to 6.2). Thus, not only the range but also the number of different ratios was restricted (HER2, 46; HER1, HER3 and HER4, 10 to 17). For HER1, these findings resulted in an accumulation of 90.3% of values at a ratio of 1.0 and 1.1, an extremely high percentage compared with its receptor relatives (HER2, 59.3%; HER3, 28.1%; HER4, 77.7%).
###end p 45
###begin p 46
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1&#8211;4 </italic>
###xml 36 40 36 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 52 62 52 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1&#8211;HER4 </italic>
###xml 93 97 93 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 191 194 191 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER</italic>
Distribution of HER1-4 FISH ratios. (a) Boxplots of HER1-HER4 FISH ratios (gene/centromere). (b) Magnified extract of (a) to demonstrate the different distribution pattern of ratios for each HER-family member.
###end p 46
###begin p 47
###xml 99 109 99 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1&#8211;HER4 </italic>
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 155 159 155 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 303 308 303 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 374 379 374 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 552 557 552 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 722 727 722 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 755 757 755 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 912 917 912 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 963 968 963 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 1039 1043 1039 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 1045 1050 1045 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 1054 1059 1054 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 1143 1145 1143 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1188 1192 1188 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 1194 1199 1194 1199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 1203 1208 1203 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 1260 1265 1260 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 849 857 <span type="species:ncbi:9606">patients</span>
###xml 898 906 <span type="species:ncbi:9606">patients</span>
###xml 949 957 <span type="species:ncbi:9606">patients</span>
With overall survival as the primary outcome measure, the plots of the martingale residuals versus HER1-HER4 FISH (Figure 4) implied the interpretation of HER1, HER3 and HER4 as continuous variables rather than dichotomising the data on the basis of a cut-off point. In contrast, the smoothed curve for HER2 FISH was roughly zero up to about 1.5 and then increased rapidly. HER2 FISH was therefore converted into a categorical variable. The results from the Contal and O'Quigley method were consistent with the results from the graphical approach. For HER2 FISH there were 46 distinct values, any of which could be defined as a potential cut-off point. The most informative value of the log rank statistic occurred at the HER2 FISH ratio of 1.5 (adjusted p = 0.086). This suggests that the cut-off point obtained is related to overall survival. The patients were therefore divided into two groups: patients with HER2 FISH ratios of 1.5 or less, and patients with HER2 FISH ratios of at least 1.6. Using the Contal and O'Quigley method for HER1, HER3 and HER4 FISH, again no cut-off point related to overall survival could be defined (adjusted p > 0.33). Consequently, in further analyses HER1, HER3 and HER4 FISH were included as continuous variables, whereas HER2 FISH was assessed as both continuous and dichotomous variables.
###end p 47
###begin p 48
###xml 38 48 38 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1&#8211;HER4 </italic>
###xml 107 115 107 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
Martingale residuals, plotted against HER1-HER4 FISH ratios, based on overall survival. FISH, fluorescence in situ hybridisation.
###end p 48
###begin p 49
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1 </italic>
###xml 258 263 258 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 286 290 286 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
The HER2 gene was amplified in most cases without evidence of polysomy, whereas both HER3 and HER4 gene alterations were usually found in combination with polysomic gene status. This finding partly explains lower FISH ratios for HER1 and, in particular, for HER3 and HER4 compared with HER2.
###end p 49
###begin p 50
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 54 55 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 182 192 182 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1&#8211;HER4 </italic>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 384 394 384 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1&#8211;HER4 </italic>
###xml 472 477 472 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 694 699 694 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 767 769 767 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 850 855 850 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 937 939 937 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 975 980 975 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1 </italic>
###xml 994 996 994 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1018 1023 1018 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 1064 1066 1064 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 457 464 <span type="species:ncbi:9606">patient</span>
###xml 572 579 <span type="species:ncbi:9606">patient</span>
FISH-dichotomised HER2 results are presented in Table 4. HER2 showed 19.9% (46 of 231) positive cases and 80.1% (185 of 231) negative cases. HR values for continuous distribution of HER1-HER4 ratios for single (1.0) and one-tenth (0.1) units are given in Table 3. The HR displays either the increase (HR > 1.0) or the decrease (HR < 1.0) of the risk of mortality by an enlargement of HER1-HER4 FISH ratio. A HR value (single unit, 1.0) of 1.16 means that a patient with a HER2 FISH ratio of 3.0, for example, has a 1.16-fold higher risk (based on overall survival) than a patient with a ratio of 2.0. Of 46 amplified cases, 40 (87.0%) also overexpressed HER2 protein. A correlation analysis of HER2 FISH and immunohistochemistry (IHC; both dichotomous) was positive (p < 0.001; correlation coefficient (CC) = 0.809). Reviewing the connection between HER3 FISH (continuous) and IHC (dichotomous), we found a significant weak correlation (p = 0.038, CC = 0.162) as well as for HER1 FISH and IHC (p = 0.010, CC = 0.200). HER4 FISH and IHC data showed no correlation (p = 0.327, CC = -0.075).
###end p 50
###begin p 51
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
Results of fluorescence in situ hybridisation (HER2) and immunohistochemical staining (HER1-HER4)
###end p 51
###begin p 52
###xml 66 68 66 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 168 176 168 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 239 244 239 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
Numbers in parentheses are percentages. The total sample size was n = 278. Results in bold define data considered positive for immunohistochemistry. FISH, fluorescence in situ hybridisation; n.r. = non-relevant for FISH; cut-off point for HER2 FISH analysis (</=1.5 vs. >/=1.6) distinguishes amplified (positive) or normal (negative) gene status.
###end p 52
###begin p 53
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 148 150 148 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 159 164 159 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 209 211 209 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 295 296 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 308 311 308 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a2</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
Patients with HER2 amplified breast cancer presented a significantly worse outcome for overall (HER2 dichotomised: HR = 2.07 (95% CI 1.33 to 3.21), p = 0.001; HER2 continuous: HR = 1.16 (95% CI 1.06 to 1.26), p = 0.001) and disease-free survival than patients with the non-amplified gene (Table 3 and Figure 5a2).
###end p 53
###begin p 54
###xml 110 120 110 120 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a1,b,c,d)</bold>
###xml 127 132 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 137 142 137 142 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a2) </bold>
###xml 230 234 230 234 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a3)</bold>
###xml 255 263 255 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
Kaplan-Meier curves of dichotomised variables, based on overall survival. Anti-HER1-HER4 immunohistochemistry (a1,b,c,d), anti-HER2 FISH (a2) and immunohistochemistry score 2+, stratified by FISH-amplified and non-amplified cases (a3). FISH, fluorescence in situ hybridisation.
###end p 54
###begin p 55
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3</italic>
###xml 103 105 103 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1 </italic>
###xml 208 210 208 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 228 233 228 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 300 302 300 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 383 384 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
In addition, HER3-positive cases had a shorter disease-free survival (HR = 2.35 (95% CI 1.08 to 5.11), p = 0.031). Amplification of HER1 caused a negative trend for survival (HR = 1.24 (95% CI 0.77 to 2.00), p = 0.380), whereas HER4 resulted in a decrease in the HR (HR = 0.36 (95% CI 0.06 to 2.36), p = 0.289). For a comparison of overall and disease-free survival values see Table 3.
###end p 55
###begin p 56
###xml 115 119 115 119 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ind </sub>
###xml 126 127 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 127 132 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HERx </italic>
###xml 127 132 127 132 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>HERx </italic></sub>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HERx </italic>
###xml 201 206 201 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1 </italic>
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 244 248 244 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 250 255 250 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 259 264 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 341 346 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 359 364 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 400 405 400 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1 </italic>
###xml 409 414 409 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 104 111 <span type="species:ncbi:9606">patient</span>
After performing univariate analysis based on overall survival, we calculated an individual HR for each patient (HRind = exp [BHERx x HERx continuous]) and plotted against the respective receptor gene HER1 to HER4 (Figure 6). In this analysis, HER1, HER2 and HER3 displayed an increasing HR with raised FISH ratios (continuous), whereas the HER4 HR declined. HER3 had the steepest curve, followed by HER1 and HER2 as next steepest.
###end p 56
###begin p 57
###xml 23 33 23 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1&#8211;HER4 </italic>
###xml 112 116 112 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ind </sub>
###xml 123 124 123 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HERx </italic>
###xml 124 129 124 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>HERx </italic></sub>
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HERx </italic>
###xml 285 293 285 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
Univariate analysis of HER1-HER4 FISH. Comparison of individually calculated hazard ratios (overall survival, HRind = exp [BHERx x HERx continuous]), based on the hazard ratio in one-tenth intervals showing the rising or declining hazard level as a function of increasing fluorescence in situ hybridisation (FISH) ratio.
###end p 57
###begin p 58
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 192 197 192 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 212 216 212 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 281 286 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 408 412 408 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ind </sub>
###xml 419 420 419 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 420 423 420 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER</italic>
###xml 420 425 420 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>HER</italic>2 </sub>
###xml 427 432 427 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 447 448 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 448 453 448 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HERx </italic>
###xml 448 453 448 453 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>HERx </italic></sub>
###xml 455 460 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HERx </italic>
###xml 484 489 484 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 576 581 576 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 636 641 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 659 660 659 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 663 667 663 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 669 674 669 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 678 683 678 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 797 798 797 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 852 857 852 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 1029 1033 1029 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 344 351 <span type="species:ncbi:9606">patient</span>
Exploring the effects of HER1, HER3 and HER4 in coexpression with HER2, HER2 results were separated into amplified and non-amplified cases (Figure 7). In a multivariate approach, dichotomised HER2 and continuous HER1, HER3 or HER4 were analysed. No significant interaction between HER2 and each of its three relatives was found. Thus, for each patient the individual HR without interaction was calculated (HRind = exp [BHER2 x HER2 dichotomised + BHERx x HERx continuous]). Amplified HER2 curves extend beyond non-amplified curves in every case, showing the greater impact of HER2 in multivariate Cox regression, visualised by adjusted HER2 HR values (Figure 7). HER1, HER3 and HER4 have additional relevance on the basis of increasing FISH ratio, given that the curves do not run parallel to the x-axis. Whereas the upper graph displays the impact of HER2 amplification dependent on increasing supplemental aberration of a second receptor, the lower curve demonstrates the exclusive impact of this receptor gene irrespective of HER2.
###end p 58
###begin p 59
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1</italic>
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 159 160 159 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 160 163 160 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER</italic>
###xml 160 165 160 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>HER</italic>2 </sub>
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 187 188 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 188 193 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HERx </italic>
###xml 188 193 188 193 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>HERx </italic></sub>
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HERx </italic>
###xml 217 222 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1 </italic>
###xml 222 225 222 225 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 227 232 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 232 236 232 236 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 245 249 245 249 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 262 270 262 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 298 303 298 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 349 354 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 398 406 <span type="species:ncbi:9606">patients</span>
Multivariate analysis of dichotomised HER2 FISH with continuous HER1, HER3 or HER4 FISH. Individually calculated hazard ratios (overall survival, HRind = EXP [BHER2 x HER2 dichotomised + BHERx x HERx continuous]) for HER1 (a), HER3 (b) and HER4 (c) fluorescence in situ hybridisation, divided into HER2 amplified (ratio >/= 1.6; filled circles) and HER2 non-amplified (ratio </= 1.5; open circles) patients.
###end p 59
###begin p 60
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 71 75 71 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a,b</xref>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1 </italic>
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 248 253 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7c</xref>
###xml 297 301 297 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4</italic>
###xml 351 356 351 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 430 435 430 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 453 458 453 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
###xml 472 479 <span type="species:ncbi:9606">patient</span>
Figure 7 suggests that the main effects are additive in nature. Figure 7a,b shows the same monotonically increasing trend: higher HER1 and HER3 values were associated with higher risk of mortality. This was valid for patients both with and without HER2 gene amplification. In contrast, Figure 7c (HER4) showed a monotonically decreasing trend: higher HER4 values were associated with a lower risk of mortality applied to both the HER2 amplified and the HER2 non-amplified patient group.
###end p 60
###begin title 61
Immunohistochemistry
###end title 61
###begin p 62
###xml 63 64 63 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 147 152 <span type="species:ncbi:10090">mouse</span>
Immunostaining of all four HER receptors was performed (Figure 1). The specificity of applied antibodies was proved by staining stably transfected mouse fibroblasts (NIH 3T3, kindly provided by Roche Diagnostics, Penzberg, Germany).
###end p 62
###begin p 63
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
For IHC, 14.5% (26 of 178) were identified as HER1 positive (score 1+, 2+ and 3+), and 85.5% (152 of 178) as negative (Table 4). In 22.4% (48 of 214) HER2 was overexpressed (score 2+ and 3+), and 77.6% (166 of 214) were normal. IHC of HER3 resulted in 75.1% (130 of 173) positive (score 1+, 2+ and 3+) and 24.9% (43 of 173) negative patients. For HER4, 37.2% (71 of 191) of cases presented overexpression (score 1+, 2+ and 3+), whereas 62.8% (120 of 191) did not.
###end p 63
###begin p 64
###xml 37 40 37 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a1</xref>
###xml 91 93 91 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 135 137 135 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 249 254 249 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 276 279 276 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a3</xref>
###xml 281 283 281 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 325 327 325 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 442 444 442 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 486 488 486 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 601 603 601 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 645 647 645 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5d</xref>
###xml 755 757 755 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 799 801 799 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 565 573 <span type="species:ncbi:9606">patients</span>
Overexpressed HER2 receptors (Figure 5a1) were associated with decreased overall survival (p = 0.129; HR = 1.42 (95% CI 0.90 to 2.25), p = 0.131), a well established observation that became unambiguously evident in cases that were scored IHC 2+ and HER2 FISH positive (Figure 5a3; p = 0.022; HR = 1.72 (95% CI 1.07 to 2.75), p = 0.024). A comparison of positive and negative HER3 cases (Figure 5c) did not yield any supplemental information (p = 0.483; HR = 0.84 (95% CI 0.51 to 1.37), p = 0.484). Immunostaining of HER1 (Figure 5b) indicated a negative effect for patients with overexpressed levels (p = 0.067; HR = 1.66 (95% CI 0.96 to 2.86), p = 0.070). In addition, HER4 protein overexpression (Figure 5d) tended to have a negative impact on disease (p = 0.068; HR = 1.48 (95% CI 0.97 to 2.26), p = 0.070).
###end p 64
###begin p 65
###xml 314 316 314 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 358 360 358 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 43 50 <span type="species:ncbi:9606">patient</span>
To examine the proliferation status in our patient cohort we assessed Ki-67 IHC. In 24% of cases (36 of 150) we documented a positive staining (more than 30% of nuclei) with a negative effect on overall survival, whereas 76% of cases (114 of 150) showed less or no staining resulting in a more favourable outcome (p = 0.142; HR = 1.49 (95% CI 0.87 to 2.55), p = 0.145).
###end p 65
###begin title 66
Discussion
###end title 66
###begin p 67
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 413 418 <span type="species:ncbi:9606">human</span>
Because screening of HER2 aberration as a prerequisite for Herceptin therapy [29-31] enables the prediction of neither the course of disease nor the individual response, the identification of additional prognostic and predictive parameters is of the utmost interest, primarily being those with immediate impact on HER2. Further investigation of the additional three, highly homologous HER2 cognate members of the human EGFR (HER-) tyrosine kinases [32] is well founded. Here we present first-hand data of a four-target FISH and IHC analysis comprising all HER receptors in breast carcinomas by using TMA. The aim of this study was to identify HER2-related molecules with additional prognostic significance within the HER family.
###end p 67
###begin p 68
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 182 187 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 376 381 376 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 491 492 491 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 493 494 493 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 144 152 <span type="species:ncbi:9606">patients</span>
We verified the known negative impact of HER2 amplification on the overall and disease-free survival of patients. The discrepancy of 13% of the patients showing amplification of the HER2 gene but not overexpression of the HER2 protein is consistent with the expected loss of IHC sensitivity associated with tissue fixation and embedding [33]. The positive correlation between HER2 FISH and HER2 IHC analysis is in accordance with the literature (up to 95% concordance between FISH and IHC) [2,6] as well as our own previous data (100% concordance between FISH and fluorescent IHC) [34].
###end p 68
###begin p 69
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 569 574 569 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1 </italic>
Similar to our FISH and IHC analysis, Tsutsui and colleagues [19] found the combination of HER1 and HER2 expression in breast cancer to have a severe negative impact on disease outcome compared with normal protein levels, whereas the prognostic value of HER2 overexpression seemed more pronounced than HER1 overexpression. However, Diermeier and colleagues [16] provided evidence that the HER1 expression level in the breast cancer cell line SK-BR-3, coexpressed with overexpressed HER2, has a key role in mediating the anti-proliferative effect of Herceptin. Overall, HER1 gene amplification or HER1 protein overexpression in this study was found to be a rare event.
###end p 69
###begin p 70
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 886 888 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1391 1395 1391 1395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 1396 1401 1396 1401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 1496 1501 1496 1501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 1505 1510 1505 1510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 1518 1519 1518 1519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 1078 1083 <span type="species:ncbi:9606">human</span>
In contrast, the data presented in this study provide striking evidence for a significance of alterations in HER3 in breast cancer. This observation is supported by Holbro and colleagues [35], who identified the function of the HER2/HER3 dimer as an oncogenic unit in which HER3 couples active HER2 to the downstream signalling phosphoinositide 3-kinase/protein kinase B pathway. Blocking HER2 resulted in antiproliferative effects accompanied by a decrease in HER3 signalling activity [36]. Although HER3 has no intrinsic kinase activity to initiate the signalling process, ligand-bound or even ligand-independent HER3 may form heterodimers with HER2 that are potent signalling complexes [37,38]. According to Liu and colleagues [39], HER3 also contributes to HER2-associated tamoxifen resistance, and a decrease in HER3 levels restores sensitivity to tamoxifen. Jones and colleagues [40] provided a quantitative protein interaction network by applying protein microarrays comprising virtually every Src homology 2 (SH2) and phosphotyrosine-binding (PTB) domain encoded in the human genome. They found a difference in the extent to which the HER receptors form protein-protein interactions when overexpressed, and consequently found the HER2-HER3 complex to have the most pronounced promiscuity with regard to activate intracellular signalling. Our results indicate the significance of the HER2/HER3 aberration in the increasing HR and therefore risk of mortality after multivariate analysis of HER2 and HER3 (Figure 7).
###end p 70
###begin p 71
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 648 652 648 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 676 681 676 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 708 713 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 749 754 749 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 762 763 762 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 815 820 815 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 869 874 869 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 963 965 963 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 987 989 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 990 992 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 993 995 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1136 1138 1136 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1261 1263 1261 1263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1281 1286 1281 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 1604 1606 1604 1606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
We detected a positive impact of HER4 on disease outcome with FISH but not with IHC analysis, as reflected by the lack of correlation between FISH and IHC data. HER4 protein overexpression has previously been described as a positive prognostic factor, a suggestion based on investigative approaches [20,41,42]. These positive effects can most probably be attributed to growth controlling and differentiation signalling. Barnes and colleagues [43] showed that HER4 decreases HER2 signalling activity by leading to decreased proliferation activity and increased apoptosis. In accordance with these data, we were also able to show via FISH analysis a HER2-compensating effect of HER4 represented by a decreased HER2 HR in the presence of alteration of HER4 (Figure 7). Furthermore, in support of a potential impact of HER4 amplification on improved outcome, we found that HER4 amplification detected by FISH was correlated with a positive oestrogen receptor status (p = 0.001, CC = 0.266) [18,44,45]. Significant correlation of HER4 positivity with low bromodeoxyuridine-derived proliferation indices as described by Tovey and colleagues [18] is associated with a good prognosis in breast cancer tumours. Contrary conclusions were reported by Vogt and colleagues [46], who found that HER4 amplification and ER activity were negatively correlated. These differences may occur as a result of the variable responses by HER4 to its activating ligand Heregulin, resulting in either proliferation or differentiation, and perhaps influenced by homodimerisation or heterodimerisation with other HER-family members [47].
###end p 71
###begin p 72
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 232 234 232 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c </italic>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 634 639 634 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 882 884 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 943 945 943 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1008 1013 1008 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 1029 1031 1029 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 144 151 <span type="species:ncbi:9606">patient</span>
###xml 696 703 <span type="species:ncbi:9606">patient</span>
Vidal and colleagues considered that the HER4 cell-killing intracellular domain 4ICD might be responsible for association with overall improved patient prognosis [48] by accumulating in mitochondria, causing an efflux of cytochrome c and resulting in mitochondrion-regulated apoptosis [49]. It is known that HER-receptor activity and signalling is variable and depends on a particular receptor coexpression profile, potentially explaining the unequivocally strong correlation between HER4 alteration/overexpression and tumour grade or proliferation index [50]. To discover a potential relationship between the proliferation index and HER4 FISH-associated positive or HER4 IHC-associated negative patient outcome, we performed Ki-67 immunostaining. Positive MIB-1 IHC resulted in a negative trend (overall survival) in a univariate analysis, which is consistent with the literature [21]. In fact, Her4 IHC and Ki-67 were positively correlated (p = 0.002, CC = 0.256), whereas no correlation was found between HER4 FISH and Ki-67 (p = 0.267, CC = -0.095). Detailed functional studies addressing the impact of HER4 in the context of well-described coexpression patterns will elucidate the importance of HER4 within the HER-receptor family.
###end p 72
###begin p 73
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 467 469 467 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 509 511 509 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 637 639 637 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
Information on HER1, HER3 and HER4 protein overexpression is extremely variable in the literature [20,44,51]; for example 16 to 36% for HER1, 18 to 26% for HER3 and 12 to 82% for HER4, but is usually similar for HER2 (23 to 27%). Our data fell within these ranges, except for HER3 IHC results (75%). With regard to a HER2 coexpression profile, 18.4% of cases additionally overexpressed HER1, 85.0% HER3 and 71.4% HER4. Although the protein statuses of HER2 and HER3 (p = 0.013, CC = 0.197) and HER2 and HER4 (p < 0.001, CC = 0.446) were significantly correlated with one another, no such correlation was found between HER2 and HER1 IHC (p = 0.654, CC = 0.035), an observation supported by the results of Hudelist and colleagues [41].
###end p 73
###begin p 74
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 656 657 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 819 821 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 427 435 <span type="species:ncbi:9606">patients</span>
Overall, the quality of immunohistochemical studies seems to be highly inconsistent because of several factors such as individual tissue preparation, the application of different detection antibodies with different binding specificity, and user-dependent interpretation of staining pattern and intensity [52]. Hence, as demonstrated for HER2, in contrast to FISH, IHC is most probably the less reliable tool for discriminating patients on the basis of alterations in HER receptors [33,53]. Particularly with regard to HER3 and HER4, numerous antibodies are commercially available from which we could prove only one to be specific for each receptor (Figure 1). Furthermore, HER-receptor overexpression can change during breast cancer development, and both a decrease and an increase in expression have been observed [42,54], additionally challenging the interpretation of staining results.
###end p 74
###begin p 75
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 211 216 211 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER1 </italic>
###xml 256 261 256 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2 </italic>
###xml 273 278 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 307 312 307 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 392 397 392 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 472 477 472 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 581 586 581 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 686 690 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3</italic>
###xml 700 708 700 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
In addition, the prognostic value of HER-family mRNA expression has been a matter of controversy. Bieche and colleagues [55], using real-time quantitative RT-PCR in patients with known long-term survival, found HER1 to be underexpressed in 82.3% of cases, HER2 (16.9%) and HER3 (46.2%) to overexpressed and HER4 both underexpressed (29.2%) and overexpressed (24.6%). Among patients with high HER4 mRNA levels, a shorter recurrence-free survival was found, suggesting that HER4 mRNA status might reflect a marker of poor outcome. However, Zaczek and colleagues [56] recently linked HER4 amplification (differential-display PCR) to favourable characteristics, as well as higher levels of HER3. RNA-RNA in situ hybridisation might clarify any discrepancy between gene and protein states and might fill an information gap.
###end p 75
###begin p 76
###xml 27 34 <span type="species:ncbi:9606">patient</span>
###xml 83 90 <span type="species:ncbi:9606">patient</span>
###xml 221 228 <span type="species:ncbi:9606">patient</span>
Further subdivision of the patient cohort into subgroups with regard to individual patient treatment or additional clinical parameters was not considered in the study presented here but should be investigated in a larger patient cohort to examine the predictive value of HER1 to HER4.
###end p 76
###begin title 77
Conclusion
###end title 77
###begin p 78
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 315 320 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 484 489 484 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 500 505 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER4 </italic>
###xml 832 839 <span type="species:ncbi:9606">patient</span>
FISH with hybridisation probes targeted to all genes encoding HER receptors turned out to be a sensitive and reliable tool for detecting potential alterations in breast cancer. Although the dominant importance of HER2 over other HER receptors is globally accepted [19], we were able to show a substantial impact of HER3 amplification on outcome of breast cancer disease (disease-free survival) even at low amplification rates. Our data provide initial evidence for the integration of HER3 as well as HER4 analysis into the diagnosis of breast cancer. Investigations are currently under way to determine the clinical importance of individual but interrelated alterations in HER in breast cancer at both the gene and protein levels. An integrated quantification of individual patterns of HER-receptor alterations may enable optimised patient stratification with respect to disease outcome. The quantification of the activated receptor relative to the unactivated protein is a promising approach, particularly with regard to therapeutic response. Further descriptive and functional studies of HER receptors will serve to characterise the disease in terms of a given molecular HER-receptor equivalent, thus providing an essential basis for individualised therapy.
###end p 78
###begin title 79
Abbreviations
###end title 79
###begin p 80
###xml 188 196 185 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 217 222 <span type="species:ncbi:9606">human</span>
B = regression coefficient beta; CC = correlation coefficient; CI = confidence interval; DAPI = 4',6-diamidino-2-phenylindole; EGFR = epidermal growth factor receptor; FISH = fluorescence in situ hybridisation; HER = human EGFR related; HR = hazard ratio; IHC = immunohistochemistry; RTK = receptor tyrosine kinase; SSC = standard saline citrate; TMA = tissue microarray.
###end p 80
###begin title 81
Competing interests
###end title 81
###begin p 82
The authors declare that they have no competing interests.
###end p 82
###begin title 83
Authors' contributions
###end title 83
###begin p 84
AS wrote the manuscript, performed the image analysis and FISH evaluation and analysed the statistical data. JR analysed the statistical data and helped to write the manuscript. PJW performed the histological analysis. AH performed the histological analysis and interpreted the data. FH provided material to be analysed and performed primary tissue based diagnostics. SS was a co-senior author, performed the histological analysis, FISH analysis and interpreted the data. GB is the research group leader and senior author and evaluated and interpreted the data.
###end p 84
###begin title 85
Acknowledgements
###end title 85
###begin p 86
The authors thank Marietta Bock for her excellent technical assistance. We also sincerely thank Dr Monika Klinkhammer-Schalke, Tumour Centre Inc., Regensburg, for providing the clinical data. This study was supported by the Bayerische Forschungsstiftung (grant number 585/03), Munich, Germany, and ZytoVision Ltd., Bremerhaven, Germany.
###end p 86
###begin article-title 87
HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer
###end article-title 87
###begin article-title 88
###xml 43 48 <span type="species:ncbi:9606">human</span>
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
###end article-title 88
###begin article-title 89
Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?
###end article-title 89
###begin article-title 90
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients
###end article-title 90
###begin article-title 91
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
###end article-title 91
###begin article-title 92
The ErbB receptors and their role in cancer progression
###end article-title 92
###begin article-title 93
###xml 35 40 <span type="species:ncbi:9606">human</span>
The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities
###end article-title 93
###begin article-title 94
HER2 and responsiveness of breast cancer to adjuvant chemotherapy
###end article-title 94
###begin article-title 95
Herceptin: increasing survival in metastatic breast cancer
###end article-title 95
###begin article-title 96
Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer
###end article-title 96
###begin article-title 97
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
###end article-title 97
###begin article-title 98
HER2 therapy: molecular mechanisms of trastuzumab resistance
###end article-title 98
###begin article-title 99
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
###end article-title 99
###begin article-title 100
Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer
###end article-title 100
###begin article-title 101
Growth factor receptors in breast cancer: potential for therapeutic intervention
###end article-title 101
###begin article-title 102
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation
###end article-title 102
###begin article-title 103
Cell signaling by receptor tyrosine kinases
###end article-title 103
###begin article-title 104
###xml 12 17 <span type="species:ncbi:9606">human</span>
Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling
###end article-title 104
###begin article-title 105
Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer
###end article-title 105
###begin article-title 106
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer
###end article-title 106
###begin article-title 107
###xml 105 113 <span type="species:ncbi:9606">patients</span>
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients
###end article-title 107
###begin article-title 108
###xml 79 87 <span type="species:ncbi:9606">patients</span>
HER2/neu expression in relation to clinicopathologic features of breast cancer patients
###end article-title 108
###begin article-title 109
Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation
###end article-title 109
###begin article-title 110
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors
###end article-title 110
###begin article-title 111
Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies
###end article-title 111
###begin article-title 112
An application of changepoint methods in studying the effect of age on survival in breast cancer
###end article-title 112
###begin article-title 113
###xml 61 64 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
Cutpoint determination methods in survival analysis using SAS(R)
###end article-title 113
###begin article-title 114
Finding optimal cutpoints for continuous covariates with binary and time-to-event outcomes
###end article-title 114
###begin article-title 115
###xml 46 51 <span type="species:ncbi:9606">human</span>
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer
###end article-title 115
###begin article-title 116
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
###end article-title 116
###begin article-title 117
Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis
###end article-title 117
###begin article-title 118
Untangling the ErbB signalling network
###end article-title 118
###begin article-title 119
###xml 80 85 <span type="species:ncbi:9606">human</span>
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry
###end article-title 119
###begin article-title 120
Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer
###end article-title 120
###begin article-title 121
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
###end article-title 121
###begin article-title 122
Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells
###end article-title 122
###begin article-title 123
The deaf and the dumb: the biology of ErbB-2 and ErbB-3
###end article-title 123
###begin article-title 124
Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3
###end article-title 124
###begin article-title 125
Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells
###end article-title 125
###begin article-title 126
A quantitative protein interaction network for the ErbB receptors using protein microarrays
###end article-title 126
###begin article-title 127
###xml 40 45 <span type="species:ncbi:9606">human</span>
Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors
###end article-title 127
###begin article-title 128
Epidermal growth factor receptor changes during breast cancer metastasis
###end article-title 128
###begin article-title 129
Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast
###end article-title 129
###begin article-title 130
EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival
###end article-title 130
###begin article-title 131
Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors
###end article-title 131
###begin article-title 132
###xml 87 92 <span type="species:ncbi:9606">human</span>
Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer
###end article-title 132
###begin article-title 133
###xml 82 87 <span type="species:ncbi:9606">human</span>
Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells
###end article-title 133
###begin article-title 134
A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities
###end article-title 134
###begin article-title 135
The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells
###end article-title 135
###begin article-title 136
The cellular response to neuregulins is governed by complex interactions of the erbB receptor family
###end article-title 136
###begin article-title 137
Type 1 protein tyrosine kinases in benign and malignant breast lesions
###end article-title 137
###begin article-title 138
The HER4 cytoplasmic domain, but not its c-terminus, inhibits mammary cell proliferation
###end article-title 138
###begin article-title 139
HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques
###end article-title 139
###begin article-title 140
ErbBs in mammary development
###end article-title 140
###begin article-title 141
Prognostic value of ERBB family mRNA expression in breast carcinomas
###end article-title 141
###begin article-title 142
Gene copy numbers of HER family in breast cancer
###end article-title 142

